SPY315.92-1.13 -0.36%
DIA260.77-2.23 -0.85%
IXIC10,436.04+2.39 0.02%

Oppenheimer Downgrades Intercept Pharmaceuticals to Perform, Lowers Price Target to $46

Oppenheimer analyst Jay Olson downgrades Intercept Pharmaceuticals (NASDAQ:ICPT) from Outperform to Perform and lowers the price target from $124 to $46.

Benzinga · -
Oppenheimer analyst Jay Olson downgrades Intercept Pharmaceuticals (NASDAQ: ICPT) from Outperform to Perform and lowers the price target from $124 to $46.